CA2370948C - Homologue du facteur de croissance zvegf4 - Google Patents

Homologue du facteur de croissance zvegf4 Download PDF

Info

Publication number
CA2370948C
CA2370948C CA2370948A CA2370948A CA2370948C CA 2370948 C CA2370948 C CA 2370948C CA 2370948 A CA2370948 A CA 2370948A CA 2370948 A CA2370948 A CA 2370948A CA 2370948 C CA2370948 C CA 2370948C
Authority
CA
Canada
Prior art keywords
zvegf4
seq
residues
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2370948A
Other languages
English (en)
Other versions
CA2370948A1 (fr
Inventor
Teresa Gilbert
Charles E. Hart
Paul O. Sheppard
Debra G. Gilbertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of CA2370948A1 publication Critical patent/CA2370948A1/fr
Application granted granted Critical
Publication of CA2370948C publication Critical patent/CA2370948C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)

Abstract

L'invention concerne des facteurs de croissance polypeptidiques, des procédés de fabrication correspondants, des polynucléotides les codant, leurs anticorps et des procédés pour les utiliser. Ces polypeptides comprennent un segment d'acides aminés qui est identique pour au moins 70 % aux résidus 52-179 de SEQ ID NO:2 ou aux résidus 258-370 de SEQ ID NO:2. L'invention concerne aussi des multimères de ces polypeptides. Les polypeptides, les protéines multimères et les polynucléotides peuvent être utilisés dans l'étude et la régulation du développement des tissus et des cellules, en tant que composants du milieu de culture des cellules et comme agents diagnostiques.
CA2370948A 1999-05-03 2000-05-03 Homologue du facteur de croissance zvegf4 Expired - Fee Related CA2370948C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30421699A 1999-05-03 1999-05-03
US16446399P 1999-11-10 1999-11-10
US18016900P 2000-02-04 2000-02-04
US09/304,216 2000-02-04
US60/164,463 2000-02-04
US60/180,169 2000-02-04
PCT/US2000/040047 WO2000066736A1 (fr) 1999-05-03 2000-05-03 Homologue du facteur de croissance zvegf4

Publications (2)

Publication Number Publication Date
CA2370948A1 CA2370948A1 (fr) 2000-11-09
CA2370948C true CA2370948C (fr) 2012-07-31

Family

ID=27389018

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2370948A Expired - Fee Related CA2370948C (fr) 1999-05-03 2000-05-03 Homologue du facteur de croissance zvegf4

Country Status (6)

Country Link
EP (1) EP1177293A1 (fr)
JP (1) JP2002542825A (fr)
AU (1) AU4714500A (fr)
CA (1) CA2370948C (fr)
MX (1) MXPA01011158A (fr)
WO (1) WO2000066736A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064382B1 (fr) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologues aux vegf et bmp1
US7148037B2 (en) 1998-11-10 2006-12-12 Ludwig Institute For Cancer Research Platelet-derived growth factor D, DNA coding therefor, and uses thereof
US7105481B2 (en) 1998-11-10 2006-09-12 Ludwig Institute For Cancer Research Method for stimulating connective tissue growth or wound healing
ATE556090T1 (de) * 1998-11-10 2012-05-15 Ludwig Inst Cancer Res Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
EP1222279A2 (fr) * 1999-10-07 2002-07-17 Curagen Corporation Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers
AU2001272902A1 (en) * 2000-05-19 2001-12-03 Eli Lilly And Company Treating musculoskeletal disorders using lp85 and analogs thereof
US7241593B2 (en) 2002-02-11 2007-07-10 Zymogenetics, Inc. Materials and methods for preparing dimeric growth factors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024811A2 (fr) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Facteur de croissance endotheliale vasculaire
WO1999037671A1 (fr) * 1998-01-27 1999-07-29 Eli Lilly And Company Gene et proteine associes au facteur de croissance des cellules endotheliales vasculaires
ATE556090T1 (de) * 1998-11-10 2012-05-15 Ludwig Inst Cancer Res Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung
DK1137773T3 (da) * 1998-12-07 2008-12-08 Zymogenetics Inc Væsktfaktorhomolog ZVEGF3

Also Published As

Publication number Publication date
EP1177293A1 (fr) 2002-02-06
WO2000066736A1 (fr) 2000-11-09
MXPA01011158A (es) 2004-06-03
CA2370948A1 (fr) 2000-11-09
AU4714500A (en) 2000-11-17
WO2000066736B1 (fr) 2000-12-21
JP2002542825A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
US6495668B1 (en) Growth factor homolog ZVEGF4
US7658920B2 (en) Method of inhibiting the activity of growth factor homolog ZVEGF3
JP5345997B2 (ja) 成長因子相同体ｚｖｅｇｆ３
CA2370948C (fr) Homologue du facteur de croissance zvegf4
US20020081700A1 (en) Snake venom polypeptide zsnk1
MXPA01005749A (en) Growth factor homolog zvegf3

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180503

MKLA Lapsed

Effective date: 20180503